Alpha Tau Medical Ltd. (DRTS) is a clinical-stage oncology company developing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a localized alpha-radiation treatment for solid tumors. The stock has delivered a powerful run in 2026, and a widening spread of analyst price targets has renewed the question of where it heads next. Based on four verified individual analyst price targets, the calculated mean sits at roughly $17 — about 35% above the latest close of $12.62.
Four current, attributable analyst price targets were reviewed to establish the central figure. Barclays analyst Lukas Shumway carries the highest target at $30, an Overweight rating set on September 3, 2026, reflecting a bullish view on DaRT technology and its potential in recurrent glioblastoma. H.C. Wainwright's Yi Chen reiterated a Buy with a $16 target on September 1, 2026. Ladenburg Thalmann's Jeff Cohen holds a Buy with a $14 target from May 12, 2026. Piper Sandler's Jason Bednar is the outlier, reiterating a Hold with an $8 target on August 11, 2026.
Those four figures average $17.00, which rounds to a $17 central target — not an official published consensus, but a simple mean of the verified targets. The range is strikingly wide, from $8 to $30, which signals genuine disagreement about how quickly Alpha DaRT's clinical programs can convert into commercial value. Notably, Barclays raised its target sharply from $17 to $30 in early September, and H.C. Wainwright lifted its target from $15 to $16, showing upward momentum in several estimates.
At a latest verified close of $12.62, DRTS trades well below its 52-week high of $15.79 but far above its 52-week low of $3.43. Reaching $17 would require a move of roughly 35% — a substantial advance, not a marginal step. The company has no meaningful reported revenue and is unprofitable, so the path to the target depends less on near-term earnings and more on clinical and regulatory milestones that could justify a higher valuation for the Alpha DaRT platform.
The stock's market capitalization has expanded to roughly $1.17 billion, reflecting investor optimism about pipeline progress across indications including head and neck, pancreatic, brain, and prostate cancers. A sustained move toward $17 would likely require continued positive data readouts, additional analyst upgrades, and a resumption of the broader uptrend that lifted the shares earlier in 2026.
The stock's 52-week high of $15.79, set in September 2026, is the first major resistance level a move toward $17 would need to clear. Above that, the $17 target itself becomes a psychological milestone. On the downside, the 200-day simple moving average near $10.29 and the 52-week low of $3.43 mark longer-term support zones. With the price currently below its 50-day moving average near $14.44, the shares have entered a short-term correction even as the longer-term uptrend remains intact.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may vary, and no explicit horizon is stated for every target. Investors should watch the next quarterly report, with earnings estimated around mid-November 2026, as well as any clinical data releases, regulatory updates, and further analyst target revisions. For a pre-revenue biotech, pipeline progress and cash runway are as important as headline financial results.
For traders seeking a systematic edge, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening allows. Explore the AI Daily Buy/Sell Signals to see how AI-driven signals can complement your own research.
Whether DRTS can reach $17 depends on balancing a genuinely bullish fundamental thesis against a wide range of analyst opinion and the inherent risks of a pre-revenue clinical-stage company. The $17 central target, the mean of four verified analyst targets spanning $8 to $30, implies a substantial 35% advance from the $12.62 price. Supporters point to a differentiated oncology platform, a broad pipeline, and rising analyst targets, while skeptics emphasize the absence of revenue, binary trial risk, and the potential for valuation compression. The next data readouts and analyst revisions will be the clearest signposts for whether that gap narrows.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DRTS has been loosely correlated with ORMP. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DRTS jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To DRTS | 1D Price Change % | ||
|---|---|---|---|---|
| DRTS | 100% | +5.53% | ||
| ORMP - DRTS | 52% Loosely correlated | N/A | ||
| IBIO - DRTS | 32% Poorly correlated | +2.95% | ||
| ABCL - DRTS | 30% Poorly correlated | +9.53% | ||
| FDMT - DRTS | 30% Poorly correlated | +5.10% | ||
| TNXP - DRTS | 30% Poorly correlated | +0.78% | ||
More | ||||